Ernexa Therapeutics Inc. Stock Issued During Period, Shares, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Ernexa Therapeutics Inc. stock issued during period, shares, conversion of convertible securities for fiscal 2022 was 0.00 shares.
- Ernexa Therapeutics Inc. stock issued during period, shares, conversion of convertible securities for fiscal 2021 was 0.00 shares.
| Period end | Stock Issued During Period, Shares, Conversion of Convertible Securities 3 month | Stock Issued During Period, Shares, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2022-12-31 | 0.00 shares 10-K · filed 2024-03-14 | |
| 2021-12-31 | 0.00 shares 10-K · filed 2023-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |